News
Lilly shares fell after the company’s oral drug showed less weight loss than hoped. It could still be huge.
Prosecutors accused a South Florida doctor and pharmacists of selling millions of pills illegally for years. WLRN tried to ...
In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...
In a clinical trial, the company's weight loss pill resulted in a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medication. On average, participants lost 7.8% to ...
Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...
Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...
AstraZeneca and Eccogene are advancing ECC5004, a once-daily GLP-1 receptor agonist pill. Early stage trial showed a ...
Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results